Tenecteplase in Acute Ischemic Stroke
For adults with acute ischemic stroke presenting within 4.5 hours of symptom onset or last known well, administer tenecteplase 0.25 mg/kg (maximum 25 mg) as a single intravenous bolus over 5-10 seconds. This dose is now the preferred thrombolytic agent, offering equivalent efficacy to alteplase with significantly easier administration 1.
Dosing Algorithm
Standard Dosing (Within 4.5 Hours)
Use tenecteplase 0.25 mg/kg (maximum 25 mg) as a single IV bolus 1:
- <60 kg: 15 mg (3 mL)
- 60 to <70 kg: 17.5 mg (3.5 mL)
- 70 to <80 kg: 20 mg (4 mL)
- 80 to <90 kg: 22.5 mg (4.5 mL)
- ≥90 kg: 25 mg (5 mL)
For patients <50 kg with accurate weight, 1-kg band dosing may be used, but do not delay treatment to obtain exact weight—timely administration is critical 1.
Administration Details
- Route: Intravenous bolus only 2
- Speed: Push over 5-10 seconds 1
- Preparation: Reconstitute with supplied sterile water to achieve 5 mg/mL concentration 2
Evidence Base
The 2026 AHA/ASA guidelines provide a Class 1, Level A recommendation for tenecteplase 0.25 mg/kg based on multiple large phase 3 RCTs involving >6,000 patients worldwide 1. These trials consistently demonstrated noninferiority to alteplase for functional outcomes (mRS 0-1 or entire scale at 90 days) with similar safety profiles 1. The practical advantages are substantial: single bolus administration versus a 60-minute infusion reduces dosing errors and treatment delays, potentially shortening door-to-needle times 1.
Large Vessel Occlusion Considerations
For patients with large vessel occlusion (LVO) within 4.5 hours, tenecteplase 0.25 mg/kg is preferred over alteplase 3. Real-world data demonstrates:
- Higher pre-thrombectomy reperfusion rates: 14.8% vs 4.5% with alteplase (risk difference 10.3%, p=0.008) 4
- Improved 90-day functional outcomes: 47.3% vs 29.3% achieving mRS 0-2 in LVO patients (p=0.031) 4
- Better recanalization: OR 3.30 for recanalization compared to control 5, 6
Even in patients proceeding to mechanical thrombectomy, do not skip IVT with tenecteplase—administer it as bridging therapy 3.
Critical Dosing Warning
Do NOT use tenecteplase 0.4 mg/kg 1. This dose carries a Class 3 (No Benefit), Level A recommendation based on multiple trials showing:
- Increased symptomatic intracranial hemorrhage risk without functional benefit 1
- The NOR-TEST 2 trial was prematurely terminated due to worse safety and functional outcomes at this dose 1
- No additional advantages over 0.25 mg/kg with potential for harm 1
Post-Administration Monitoring
After tenecteplase administration 1:
- Admit to intensive care or stroke unit
- Neurological assessments and BP monitoring:
- Every 15 minutes during and for 2 hours after administration
- Every 30 minutes for next 6 hours
- Hourly until 24 hours post-treatment
- Blood pressure control: Maintain SBP ≤180 mmHg and DBP ≤105 mmHg
- Delay invasive procedures: Avoid nasogastric tubes, bladder catheters, or arterial lines unless absolutely necessary
- Follow-up imaging: Obtain CT or MRI at 24 hours before starting anticoagulants or antiplatelets
If the patient develops severe headache, acute hypertension, nausea, vomiting, or neurological worsening, obtain emergency head CT immediately 1.
Extended Time Window (4.5-24 Hours)
For patients presenting 4.5-24 hours after last known well, the evidence is more limited. Do NOT use tenecteplase for wake-up stroke or unknown onset selected by non-contrast CT alone 3. However, recent meta-analyses suggest potential benefit in extended windows when:
- Advanced imaging (perfusion or MRI) demonstrates salvageable tissue
- Large vessel occlusion is present
- Mechanical thrombectomy is unavailable 5, 6
This remains an area requiring further study, and current guidelines do not support routine use beyond 4.5 hours without advanced imaging selection 1, 3.
Special Populations
Pediatric patients: Safety and efficacy not established; limited data from 11 children exists but insufficient for recommendations 1
Pregnancy: Myocardial infarction and stroke are medical emergencies—life-sustaining therapy should not be withheld due to pregnancy concerns 2
Practical Implementation Advantages
Tenecteplase offers significant operational benefits over alteplase 1:
- Simplified dosing: Weight-based bands reduce calculation errors
- Faster administration: 5-10 second bolus vs 60-minute infusion
- Reduced treatment delays: Shorter door-to-needle times in real-world practice
- Easier storage: Single vial system
- Lower nursing burden: No infusion pump required
These practical advantages translate to faster treatment delivery without compromising safety or efficacy, making tenecteplase the preferred agent in contemporary stroke care 1.